Hematologic Oncology Update

Featuring perspectives from Dr Catherine C Coombs, including the following topics:Early versus delayed addition of obinutuzumab to acalabrutinib and venetoclax in treatment-naïve chronic lymphocytic leukemia (CLL) (0:00)Feasibility of discontinuation of Bruton tyrosine kinase (BTK) inhibitor therapy in CLL; minimal residual disease and disease monitoring (4:10)Ongoing Phase III trials of BTK inhibitor/B-cell lymphoma 2 inhibitor combinations in previously untreated CLL (10:05)Pirtobrutinib as first-line therapy for CLL and long-term safety data (15:22)CME information and select publications

Featuring perspectives from Dr Meletios-Athanasios (Thanos) C Dimopoulos, Dr Robert Z Orlowski and Dr Noopur Raje, moderated by Dr Orlowski, including the following topics:Introduction (0:00)New and Emerging Strategies with Bispecific Antibodies in Multiple Myeloma (MM) — Dr Raje (2:20)Utility of Antibody-Drug Conjugates for Relapsed/Refractory (R/R) MM — Dr Orlowski (23:33)Potential Role of Cereblon E3 Ligase Modulators and Other Promising Novel Agents and Strategies for R/R MM — Prof Dimopoulos (41:12)CME information and select publications

Featuring perspectives from Dr Catherine C Coombs and Dr Matthew S Davids, including the following topics:Introduction (0:00)Minimal Residual Disease Assays in Community-Based Practice (1:24)New Developments in Previously Untreated Chronic Lymphocytic Leukemia (CLL) — Dr Davids (8:12)Richter Transformation (30:43)Selection and Sequencing of Therapies for Relapsed/Refractory CLL — Dr Coombs (34:49)CME information and select publications

Dr L Elizabeth Budde, a City of Hope hematologist and lymphoma specialist, explores CD20 x CD3 bispecific antibodies in diffuse large B-cell lymphoma. She compares available therapies, monotherapy and combinations, and strategies for managing cytokine release syndrome and other toxicities. Real-world cases highlight frontline treatment, CAR-T sequencing, and biopsy-guided choices after relapse.

Featuring perspectives from Dr Ann LaCasce and Dr Stephen "Fred" Divers, moderated by Dr Divers, including the following topics:Introduction (0:00)First-Line Treatment (1:33)Bispecific Antibodies and Chimeric Antigen Receptor T-Cell Therapy (20:36)CME information and select publications

Featuring perspectives from Dr Farrukh T Awan and Dr Stephen "Fred" Divers, moderated by Dr Divers, including the following topics:Introduction (0:00)First-Line Therapy (2:48)Relapsed/Refractory Disease (39:30)CME information and select publications

Featuring perspectives from Dr Brad S Kahl, Dr Jeff Sharman and Dr Tanya Siddiqi, including the following topics:Introduction (0:00)Trials in Progress (1:12)Chronic Lymphocytic Leukemia (7:09)Diffuse Large B-Cell Lymphoma (32:35)Mantle Cell Lymphoma (58:25)Follicular Lymphoma (1:14:49)CME information and select publications

Featuring an interview with Dr Douglas W Sborov, including the following topics:DREAMM-2 trial outcomes and clinical development of antibody-drug conjugates for multiple myeloma (MM); mechanism of action of belantamab mafodotin (belamaf) and predictors of response to treatment (0:00)Perspectives on findings from the Phase III DREAMM-7 trial of belamaf combined with bortezomib/dexamethasone for relapsed/refractory MM (4:26)Progression-free survival estimates with current quadruplet induction and maintenance regimens for newly diagnosed MM (6:36)Phase I DREAMM-9 trial and ongoing evaluation of belamaf in the up-front setting (11:48)Potential integration of belamaf into the relapsed/refractory and newly diagnosed MM treatment settings (16:00)Prevention and management of ophthalmic events related to treatment with belamaf (21:27)Case: A man in his mid 60s with multiregimen-recurrent MM receives single-agent belamaf (27:49)Case: A woman in her early 70s with recurrent t(11;14) MM and disease progression on single-agent belamaf experiences a sustained response to talquetamab (33:27)Case: A man in his early 70s with heavily pretreated MM receives belamaf with bortezomib (39:53)CME information and select publications

Featuring an interview with Prof Andreas Hochhaus, including the following topics:Biology of chronic myeloid leukemia (CML) and rationale for current therapeutic approaches; importance of cytogenetic testing (0:00)Mechanistic differences among first-generation tyrosine kinase inhibitors (TKIs), second-generation TKIs and asciminib (6:09)Potential mechanisms of adverse events documented with TKIs (10:23)Recent survey of patients with CML regarding goals of therapy and clinical implications; considerations for discontinuation of therapy (16:23)Comparative tolerability of asciminib and other agents used to manage CML; promoting adherence to treatment plans for patients (27:14)Comparative efficacy of asciminib and other agents used to treat CML (40:01)Potential areas for improvement in community oncology practice patterns; family planning in the context of CML treatment (43:53)Practical care strategies for CML patients; future developments (52:32)CME information and select publications

Featuring perspectives from Prof John Seymour and cases from Dr Daniel Ermann, Dr Shazia Nakhoda and Dr Mahesh Swaminathan, including the following topics:Case: A woman in her mid 50s with multiple sclerosis, hypertension, IGHV-unmutated chronic lymphocytic leukemia (CLL) with an SF3B1 mutation and autoimmune hemolytic anemia receives acalabrutinib/venetoclax/obinutuzumab (0:00)Case: A man in his late 60s with bulky CLL diagnosed abroad receives zanubrutinib monotherapy (12:48)Case: A man in his late 40s with IGHV-mutated, del(13q) CLL with worsening symptoms and diffuse adenopathy after 1 year of observation receives venetoclax/obinutuzumab and attains a complete response (21:29)CME information and select publications